Epstein Barr Virus (EBV) Early Antigen BA1363P54VS

$1,054.00

Summary

Virion/Serion Immunologics Antigen for research use (RUO)
Epstein-Barr Virus (EBV) Early Antigen, recombinant
Suitable for detection of IgA, IgG & IgM antibodies in ELISA
Lot specific concentration, specified in mg/mL
1 mg

SKU: BA1363P54VS Category: Infectious disease proteins Tags: antigen, Epstein-Barr Virus

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Epstein Barr Virus (EBV) (early)
species reactivity	Epstein-Barr Virus (EBV) (mononucleosis, mono, glandular fever)
applications	ELISA
assay type	Indirect & quantitative
available size	1 mg

Epstein Barr Virus (EBV) Early Antigen BA1363P54VS

kit
Research area Infectious Disease
Storage Store at -65°C or lower. Avoid repeated freeze-thaw cycles. 10 years from date of manufacture (under recommended storage conditions).
Form liquid
Associated products Epstein-Barr Virus (EBV) Capsid Antigen P18, alternative buffer Control Antigen (BA1361R01) Epstein Barr Virus (EBV) Capsid Antigen (BA1361VSR21) Epstein Barr Virus (EBV) Capsid Antigen (BA1361VSR22) Epstein Barr Virus (EBV) Nuclear Antigen (BA1362VS) Epstein Barr Virus (EBV) Early Antigen (BA1363P54VS) Epstein Barr Virus (EBV) Early Antigen (BA1363VSR6) Epstein-Barr Virus VCA IgG Control Serum (BC1361G) Epstein-Barr Virus VCA IgM Control Serum (BC1361M) Epstein-Barr Virus EBNA-1 IgG Control Serum (BC1362G) Epstein-Barr Virus EA IgG Control Serum (BC1363G) Epstein-Barr Virus/VCA IgG ELISA Kit (ESR1361G) Epstein-Barr Virus/EBNA1 IgG ELISA Kit (ESR1362G)

target relevance
Epstein-Barr Virus
Description Virus that causes infectious mononucleosis and is associated with several human cancers
Structure Epstein-Barr virus (EBV), also known as Human herpesvirus 4 (HHV-4), is an enveloped, double-stranded DNA virus belonging to the genus Lymphocryptovirus within the family Herpesviridae. The virus possesses an icosahedral nucleocapsid surrounded by a protein tegument and a lipid envelope containing multiple viral glycoproteins involved in host cell attachment and entry. EBV primarily infects B lymphocytes and epithelial cells and establishes lifelong latent infection following primary exposure. More than 90% of the world's adult population carries the virus. During latency, EBV persists within memory B cells and can periodically reactivate, resulting in viral shedding and transmission. EBV is associated with several malignancies, including Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, gastric carcinoma, and post-transplant lymphoproliferative disorders.
Diagnosis The diagnosis of Epstein-Barr virus infection is performed through serological, molecular, and hematological methods. Detection of heterophile antibodies using the Monospot test is commonly used for the diagnosis of infectious mononucleosis, although sensitivity may vary depending on age and stage of infection. EBV-specific serological assays measuring antibodies against viral capsid antigen (VCA), early antigen (EA), and Epstein-Barr nuclear antigen (EBNA) provide valuable information regarding acute, past, or reactivated infection. Molecular methods such as quantitative polymerase chain reaction (PCR) are used to detect and monitor viral DNA, particularly in immunocompromised patients and individuals at risk of EBV-associated malignancies. Hematological findings often include atypical lymphocytosis during acute infection.
Symptoms Epstein-Barr virus is primarily transmitted through saliva and is often referred to as the cause of the 'kissing disease.' Following an incubation period of approximately four to six weeks, primary infection may result in infectious mononucleosis characterized by fever, fatigue, sore throat, enlarged lymph nodes, headache, and splenomegaly. Many infections in childhood are asymptomatic or cause only mild illness. Fatigue may persist for weeks or months following acute infection. In immunocompromised individuals, EBV can cause severe lymphoproliferative disease and contribute to the development of certain cancers. Although most infections resolve without complications, rare severe manifestations include hepatitis, neurological complications, hemolytic anemia, and splenic rupture.

Data

FAQ & Publications

Frequently Asked Questions

What is the primary application of the Epstein Barr Virus (EBV) Early Antigen BA1363P54VS?

The Epstein Barr Virus (EBV) Early Antigen BA1363P54VS is primarily used for the detection of IgA, IgG, and IgM antibodies in ELISA assays, providing an indirect and quantitative method for research purposes.

How should the EBV Early Antigen BA1363P54VS be stored to maintain its stability?

The product should be stored at -65°C or lower, and repeated freeze-thaw cycles should be avoided to preserve its integrity. Under these recommended storage conditions, it has a shelf life of 10 years from the date of manufacture.

Is the EBV Early Antigen BA1363P54VS suitable for detecting antibodies from human samples?

Yes, the antigen is reactive to Epstein-Barr Virus, which infects humans, and is suitable for research involving human immune responses, specifically for detecting IgA, IgG, and IgM antibodies against EBV early antigens.

What format is the EBV Early Antigen BA1363P54VS provided in, and what is the typical amount supplied?

This product is supplied in a liquid form with a lot-specific concentration detailed in mg/mL, and it is available in a 1 mg size suitable for research applications.

Can the EBV Early Antigen BA1363P54VS be used to identify acute primary EBV infections?

Yes, IgG antibodies against early antigen (EA) detected using this antigen, especially when combined with IgM antibodies against virus capsid antigens and negative EBNA1 IgG activity, serve as evidence of acute primary EBV infections.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.